Benefits of PARP inhibitor rechallenge in patients with platinum-sensitive recurrent ovarian cancer previously treated with a PARP inhibitor: a multicenter retrospective study.

Authors

Ami Jo, Tadahiro Shoji, Ayaka Kitamura, Miku Musashi, Shunsuke Tatsuki, Nanako Jonai, Yohei Chiba, Sho Sato, Eriko Takatori, Yoshitaka Kaido, Takayuki Nagasawa, Masahiro Kagabu, Fumiaki Takahashi, Takeshi Aida, Tsukasa Baba

Published in

International journal of clinical oncology. Aug 07, 2026. Epub Aug 07, 2026.

Abstract

Although poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) rechallenge has been explored for platinum-sensitive recurrent ovarian cancer, data in Japanese patients remain scarce. This retrospective study evaluated the safety and efficacy of PARPi rechallenge in this population.
Twenty-eight Japanese patients with ovarian cancer who experienced platinum-sensitive recurrence during or after PARPi therapy and subsequently responded to platinum-based chemotherapy were included. Olaparib and niraparib were administered as PARPi rechallenge in 19 and 9 patients, respectively. The primary endpoint was progression-free survival (PFS), and secondary endpoints were overall survival (OS) and adverse events (AEs).
The median follow-up period was 19 months (range, 3-47). Median PFS and OS in the overall population were 6 months (95% CI, 3-8) and 32 months (95% CI, 28-not reached), respectively. The median PFS for patients who had received two prior regimens was 6 months, compared with 5 months for those who had received three or more regimens, with no significant difference (P = 0.734). Grade ≥3 hematologic toxicities included neutropenia (n = 4), anemia (n = 7), and thrombocytopenia (n = 2). Non-hematologic toxicities included interstitial pneumonia, hypertension, and proteinuria, with one case each. No treatment-related deaths occurred.
PARPi rechallenge in Japanese patients with platinum-sensitive recurrent ovarian cancer demonstrated a manageable safety profile but limited efficacy. Larger, prospective studies incorporating molecular stratification are required to better define the clinical role of PARPi rechallenge.

PMID:
42566090
Bibliographic data and abstract were imported from PubMed on 07 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.